We previously reported an ABD-fused RM26peptide targeting GRPR (ABD-RM26 Gen 1) that showed prolonged andstable tumor uptake over 144 h; however, the observed high kidneyuptake indicated that the conjugate’s binding to albumin wasreduced and that this could be an obstacle for its use as a deliverysystem for targeted therapy, especially for radiotherapy. This evidence concerns the gene ALB and neoplasm.